Capricor Therapeutics, Inc. (NASDAQ:CAPR - Get Free Report) shares crossed below its fifty day moving average during trading on Wednesday. The stock has a fifty day moving average of $8.05 and traded as low as $7.99. Capricor Therapeutics shares last traded at $8.03, with a volume of 8,343,622 shares.
Wall Street Analysts Forecast Growth
CAPR has been the topic of a number of recent research reports. JonesTrading upgraded shares of Capricor Therapeutics from a "hold" rating to a "buy" rating and set a $25.00 price target on the stock in a research note on Wednesday, November 11th. Wall Street Zen lowered shares of Capricor Therapeutics from a "sell" rating to a "strong sell" rating in a research note on Saturday, August 1st. Alliance Global Partners lowered Capricor Therapeutics from a "buy" rating to a "neutral" rating and set a $7.00 price objective on the stock. in a research note on Tuesday, July 28th. Roth Capital reissued a "neutral" rating and set a $10.50 price objective (up from $7.00) on shares of Capricor Therapeutics in a report on Friday, November 13th. Finally, Ladenburg Thalmann & Co. Inc. downgraded Capricor Therapeutics from a "buy" rating to a "neutral" rating in a research note on Thursday, July 30th. Five investment analysts have rated the stock with a Buy rating, five have given a Hold rating and one has given a Sell rating to the company's stock. According to MarketBeat.com, Capricor Therapeutics has a consensus rating of "Hold" and an average target price of $30.09.
View Our Latest Report on CAPR
Capricor Therapeutics Stock Down 4.5%
The company has a market cap of $466.86 million, a PE ratio of -3.04 and a beta of 0.80. The stock has a 50-day moving average of $8.05 and a 200-day moving average of $19.65.
Capricor Therapeutics (NASDAQ:CAPR - Get Free Report) last posted its earnings results on Tuesday, November 10th. The biotechnology company reported ($0.73) EPS for the quarter, missing the consensus estimate of ($0.44) by ($0.29). Research analysts expect that Capricor Therapeutics, Inc. will post -2.39 EPS for the current year.
Institutional Inflows and Outflows
Several institutional investors have recently modified their holdings of the stock. RA Capital Management L.P. lifted its position in Capricor Therapeutics by 99.9% during the third quarter. RA Capital Management L.P. now owns 3,014,183 shares of the biotechnology company's stock valued at $28,544,000 after purchasing an additional 1,506,339 shares during the last quarter. Jump Financial LLC increased its holdings in shares of Capricor Therapeutics by 1,984.9% in the 3rd quarter. Jump Financial LLC now owns 480,286 shares of the biotechnology company's stock worth $4,548,000 after buying an additional 457,250 shares during the last quarter. Bank of America Corp DE increased its holdings in shares of Capricor Therapeutics by 672.0% in the 1st quarter. Bank of America Corp DE now owns 415,483 shares of the biotechnology company's stock worth $12,631,000 after buying an additional 361,664 shares during the last quarter. Montanova Capital LLC increased its holdings in shares of Capricor Therapeutics by 7.2% in the 2nd quarter. Montanova Capital LLC now owns 4,092,784 shares of the biotechnology company's stock worth $98,554,000 after buying an additional 274,184 shares during the last quarter. Finally, Walleye Capital LLC purchased a new stake in shares of Capricor Therapeutics during the 1st quarter valued at $5,397,000. 21.68% of the stock is currently owned by institutional investors.
About Capricor Therapeutics
(
Get Free Report)
Capricor Therapeutics is a biotechnology company developing cell- and exosome-based therapies for serious diseases. Its research focuses on using these technologies to address conditions with limited treatment options. The company's leading program is deramiocel, also known as CAP-1002, an investigational therapy made from donor-derived cardiac cells. Capricor is developing it for Duchenne muscular dystrophy, a rare genetic disorder that causes progressive muscle weakness. Capricor is also advancing an exosome-based technology platform for potential therapeutic applications.
Further Reading
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Capricor Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Capricor Therapeutics wasn't on the list.
While Capricor Therapeutics currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.